Genitourinary Cancer News

Adjuvant nivolumab significantly prolonged DFS compared with placebo for patients with high-risk, muscle-invasive urothelial carcinoma, according to topline data released by the agent’s manufacturer.

Nivolumab plus cabozantinib conferred superior PFS, OS and response rates compared with sunitinib as a first-line treatment for advanced renal cell carcinoma, according to results of a phase 3 study presented at ESMO Virtual Congress 2020.

Adults who received radiation therapy during childhood for abdominal and pelvic cancers appeared more likely than the general population to experience body composition abnormalities and worse cardiometabolic outcomes, study results showed.

The FDA granted priority review to durvalumab for administration in a 4-week, fixed dose regimen for the treatment of patients with non-small cell lung cancer and bladder cancer, according to a manufacturer-issued press release.

Cytoreductive nephrectomy may extend OS for a well-selected population of patients with metastatic renal cell carcinoma, according to study results published in Cancer.

Black children with solid cancers appeared less likely to receive proton radiotherapy than their white counterparts, according to an analysis of Children’s Oncology Group trial data published in a research letter in JAMA Oncology.

The FDA granted breakthrough therapy designation to MK-6482 for the treatment of certain patients with von Hippel-Lindau disease-associated renal cell carcinoma, according to a press release from the agent’s manufacturer.

These are times when, under assault from the COVID-19 pandemic and many parts of government, those of us who are relatively powerless can seek to regain control by influencing what we can influence.

Percutaneous cryoablation appeared safe and improved 10-year survival outcomes compared with partial or radical nephrectomy among patients with early-stage renal cell carcinoma, according to study results published in Radiology.

Atezolizumab plus platinum-based chemotherapy prolonged PFS as first-line therapy for patients with metastatic urothelial carcinoma, according to results of the randomized phase 3 IMvigor130 trial published in The Lancet.